-
MDMA therapy reduces PTSD symptoms in phase 3 study
The potential is growing for MDMA-assisted therapy, also known as ecstasy, to be approved for treating PTSD as more research finds success. -
FDA to weigh public comments before making decision on common decongestant
Following an FDA advisory committee's determination that a common ingredient in over-the-counter cough and cold medicines is ineffective, the agency released a statement clarifying it has not yet made a final decision on the matter. -
FTC cracks down on improper drug patent filings
The Federal Trade Commission is targeting brand-name drugmakers that are improperly listing patents, which can weaken competition. -
New COVID vaccines aren't boosters, experts say
The updated fall COVID-19 vaccines that are beginning to roll out are not booster shots. Experts say there is an important distinction between what constitutes a booster shot and these newly formulated vaccines, CBS News reported Sept. 15. -
Local PBM market is dwindling, AMA finds
Six pharmacy benefit managers account for 96 percent of the industry's market share, and their lead is growing, according to an analysis from the American Medical Association. -
J&J rebrands, cuts script logo
Johnson & Johnson is reinventing itself by renaming its pharmaceutical segment and changing its logo, the company said Sept. 14. -
Mount Sinai gets $13M to create next-gen coronavirus vaccines
The National Institutes of Health has awarded New York City-based Icahn School of Medicine at Mount Sinai a five-year, $13 million grant to develop new coronavirus vaccines. -
CMS adds 34 drugs to list of Medicare savings
CMS has named 34 prescription drugs that could have lower out-of-pocket costs for those on Medicare, potentially saving up to $618 per dose. -
U of Wisconsin offers PharmD pathway for high schoolers, undergrads
The University of Wisconsin-Madison's pharmacy school unveiled a new avenue that guarantees admission for high schoolers and first-year undergrads into its PharmD program. -
California found 'major deficiencies' at hospital pharmacy on probation
The California State Board of Pharmacy documented "major deficiencies" related to staff training and knowledge in 2019 at Sutter Coast Hospital's compounding pharmacy, which was recently placed on a three-year probation. -
50 drugs at Mark Cuban's pharmacy with biggest cost reductions
In 2023, Mark Cuban Cost Plus Drug Co. began selling two generic medications cheaper than their branded versions by more than $10,000. -
FDA warns CVS, Walgreens against selling unapproved eye products
The FDA sent warning letters Sept. 12 to CVS, Walgreens and six other companies for illegally marketing unapproved eye drug products. -
1 cancer drug in shortage nearing 100% resupply, White House says
Cisplatin, a drug used for multiple types of cancer that's been in a severe shortage for months, is close to returning to 100 percent of pre-shortage supply levels, the White House said Sept. 12. -
6 systems tap Shields specialty pharmacy
Shields Health Solutions, a specialty pharmacy solutions company, has secured new partnerships with six systems in 2023, adding to its portfolio of about 850 hospitals. -
Common decongestant is ineffective, FDA panel rules
A 16-person FDA advisory panel agreed Sept. 12 that oral phenylephrine, an ingredient commonly found in over-the-counter cold and allergy medications, does not help with nasal congestion. -
25th drugmaker imposes restriction on 340B participants
Jazz Pharmaceuticals is the latest drugmaker to impose pricing restrictions for 340B participants, according to a Sept. 11 news release from the 340B Health organization. Its decision makes it the 25th drugmaker to impose the restrictions since 2020. -
FDA to vote on whether key ingredient in common cold meds is ineffective
FDA advisory members are meeting Sept. 11-12 to vote on whether phenylephrine should be reclassified as ineffective amid data suggesting the common ingredient in over-the-counter cold medicines does not relieve symptoms when taken orally. -
Novartis recalls drug lot after crystals form in bottles
Novartis pulled one drug lot from the market after finding crystal formation in some bottles, which could lead to incorrect dosing, the FDA said Sept. 11. -
FDA, CDC greenlight updated boosters
On Sept. 12, the CDC director delivered the final stamp of approval to XBB.1.5-focused COVID-19 boosters, which could be available to the public later this week. -
Ozempic and suicidal thoughts: What to know as Europe reviews
In July, the European Medicines Agency began reviewing GLP-1 receptor agonists, including Ozempic, Saxenda and Wegovy, because of Icelandic patients reporting thoughts of suicide and self-harm. The U.S. has not launched a similar probe.
Page 44 of 50